Amazon to Expand Drone Delivery to 500 U.S. Locations 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Trump Buys SpaceX Shares After Record IPO 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Add as a preferred source on Google
SAN CARLOS, Calif., May 02, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in May:
- Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 2:50 p.m. ET
- UBS Global Healthcare Conference in New York, NY on Monday, May 21, 2018 at 2:30 p.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
